论文部分内容阅读
根治間日瘧,是瘧疾研究和防治工作的重要課題。目前,抗瘧药的发現和合成,已为数不少。1946年伯氨喹啉合成后,世界各地陆續实驗和应用,一致認为伯氨喹啉为8—氨喹啉类药物中,疗效最高,毒性最低的一种,系当前根治間日瘧的良好药物。乙氨嘧啶(国內通称息瘧定,下同)合成后,咸認为該药为預防瘧疾的較好药物。上述两药虽各有所长,但仍有各自的不足。为提高疗效,改进疗程,互取其长,以期取得增效的目的,我們于1962年,在金乡县将二药合并用于瘧疾抗复发治疗。現簡介于下,以供同道参考。
Eradication of vivax malaria is an important issue in the research and prevention and treatment of malaria. At present, the discovery and synthesis of anti-malaria drugs have been quite a few. After the synthesis of primaquine in 1946, one after another in various parts of the world, it was agreed that primaquine was the most effective and the least toxic one among 8-aminoquinolines, Good medicine. Propyl pyrimidine (domestic known interest malaria, the same below) synthesis, salty that the drug for the prevention of malaria better medicine. Although the two drugs have their own strengths, but still have their own deficiencies. In order to improve the curative effect, improve the course of treatment, and take the lead from each other in order to achieve synergies, we combined the two drugs in Jinxiang County in 1962 for anti-relapse treatment of malaria. Brief introduction is below, for fellow reference.